Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
First Claim
Patent Images
1. A synthetic, modified oligonucleotide of 14 to 30 nucleotides in length wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is an antisense compound which specifically hybridizes and is 100% complementary to a complementary region of a natural antisense polynucleotide of a Hepatocyte Growth Factor (HGF) gene and wherein said natural antisense polynucleotide is selected from the group consisting of SEQ ID NO;
4 and upregulates the function and/or expression of a Hepatocyte Growth Factor (HGF) gene in vivo or in vitro as compared to a normal control.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Hepatocyte Growth Factor (HGF), in particular, by targeting natural antisense polynucleotides of Hepatocyte Growth Factor (HGF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of HGF.
196 Citations
16 Claims
-
1. A synthetic, modified oligonucleotide of 14 to 30 nucleotides in length wherein the at least one modification is selected from:
- at least one modified sugar moiety;
at least one modified internucleotide linkage;
at least one modified nucleotide, and combinations thereof;
wherein said oligonucleotide is an antisense compound which specifically hybridizes and is 100% complementary to a complementary region of a natural antisense polynucleotide of a Hepatocyte Growth Factor (HGF) gene and wherein said natural antisense polynucleotide is selected from the group consisting of SEQ ID NO;
4 and upregulates the function and/or expression of a Hepatocyte Growth Factor (HGF) gene in vivo or in vitro as compared to a normal control. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
- at least one modified sugar moiety;
Specification